Atkins HL[au] - Search Results

Year	Number of Results
1957	1
1960	1
1961	4
1962	2
1963	1
1964	3
1965	3
1966	4
1967	4
1968	8
1969	2
1970	8
1971	11
1972	9
1973	9
1974	4
1975	8
1976	4
1977	8
1978	7
1979	7
1980	8
1981	8
1982	3
1983	3
1984	5
1985	7
1986	6
1987	5
1988	1
1989	6
1990	4
1991	2
1992	2
1993	3
1994	2
1995	3
1996	6
1997	2
1998	4
1999	2
2000	1
2003	1
2004	1
2005	1
2006	3
2007	3
2008	1
2009	1
2010	3
2011	3
2012	5
2013	5
2014	4
2015	2
2016	4
2017	4
2018	3
2019	5
2020	3
2021	3
2022	1

1

Autologous hematopoietic stem cell transplantation for multiple sclerosis: A current perspective.

Bose G, Thebault S, Rush CA, Atkins HL, Freedman MS. Bose G, et al. Among authors: atkins hl. Mult Scler. 2021 Feb;27(2):167-173. doi: 10.1177/1352458520917936. Epub 2020 May 4. Mult Scler. 2021. PMID: 32364422

2

Closing volume.

Susskind H, Richards P, Atkins HL. Susskind H, et al. Among authors: atkins hl. Lancet. 1973 Mar 17;1(7803):603-4. doi: 10.1016/s0140-6736(73)90746-0. Lancet. 1973. PMID: 4120664 No abstract available.

3

A real-world single-centre analysis of alemtuzumab and cladribine for multiple sclerosis.

Bose G, Rush C, Atkins HL, Freedman MS. Bose G, et al. Among authors: atkins hl. Mult Scler Relat Disord. 2021 Jul;52:102945. doi: 10.1016/j.msard.2021.102945. Epub 2021 Apr 11. Mult Scler Relat Disord. 2021. PMID: 33901969

4

Does Resetting the Immune System Fix Multiple Sclerosis?

Bose G, Thebault SDX, Atkins HL, Freedman MS. Bose G, et al. Among authors: atkins hl. Can J Neurol Sci. 2020 Jan;47(1):1-10. doi: 10.1017/cjn.2019.294. Epub 2019 Oct 18. Can J Neurol Sci. 2020. PMID: 31511117

5

Neurotoxicity after hematopoietic stem cell transplant in multiple sclerosis.

Thebault S, Lee H, Bose G, Tessier D, Abdoli M, Bowman M, Berard J, Walker L, Rush CA, MacLean H, Booth RA, Narayanan S, Arnold DL, Tabard-Cossa V, Atkins HL, Bar-Or A, Freedman MS. Thebault S, et al. Among authors: atkins hl. Ann Clin Transl Neurol. 2020 May;7(5):767-775. doi: 10.1002/acn3.51045. Epub 2020 Apr 18. Ann Clin Transl Neurol. 2020. PMID: 32304358 Free PMC article.

6

Personalized oncology and BRAF^K601N melanoma: model development, drug discovery, and clinical correlation.

Keller BA, Laight BJ, Varette O, Broom A, Wedge MÈ, McSweeney B, Cemeus C, Petryk J, Lo B, Burns B, Nessim C, Ong M, Chica RA, Atkins HL, Diallo JS, Ilkow CS, Bell JC. Keller BA, et al. Among authors: atkins hl. J Cancer Res Clin Oncol. 2021 May;147(5):1365-1378. doi: 10.1007/s00432-021-03545-2. Epub 2021 Feb 8. J Cancer Res Clin Oncol. 2021. PMID: 33555379

7

Autologous Hematopoietic Stem Cell Transplantation in the Treatment of Multiple Sclerosis.

Rush CA, Atkins HL, Freedman MS. Rush CA, et al. Among authors: atkins hl. Cold Spring Harb Perspect Med. 2019 Mar 1;9(3):a029082. doi: 10.1101/cshperspect.a029082. Cold Spring Harb Perspect Med. 2019. PMID: 29610145 Free PMC article. Review.

8

Hematopoietic stem cell therapy for multiple sclerosis: top 10 lessons learned.

Atkins HL, Freedman MS. Atkins HL, et al. Neurotherapeutics. 2013 Jan;10(1):68-76. doi: 10.1007/s13311-012-0162-5. Neurotherapeutics. 2013. PMID: 23192675 Free PMC article. Review.

9

Overview of nuclides for bone pain palliation.

Atkins HL. Atkins HL. Appl Radiat Isot. 1998 Apr;49(4):277-83. doi: 10.1016/s0969-8043(97)00039-0. Appl Radiat Isot. 1998. PMID: 9519437 Review.

10

Haematopoietic stem cell transplants should be a second-line therapy for highly active MS - YES.

Freedman M, Atkins HL. Freedman M, et al. Among authors: atkins hl. Mult Scler. 2016 Sep;22(10):1258-9. doi: 10.1177/1352458516654311. Epub 2016 Jul 21. Mult Scler. 2016. PMID: 27444560 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results